Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report By Source, By Service (Upstream, Downstream, Fill/Finish), By Product (Biologics), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global Biopharmaceuticals Contract Manufacturing market size was exhibited at USD 19.0 billion in 2023 and is projected to hit around USD 32.15 billion by 2033, growing at a CAGR of 5.4% during the forecast period 2024 to 2033.

Key Pointers:

  • The U.S., North America dominated with the largest revenue share of 37% in 2023.
  • The mammalian source segment led the market in 2023 and accounted for the highest share of 60.9%. 
  • Process development services led the global market in 2023 and accounted for a share of about 34.7%.
  • The biologics product segment led the market in 2023 with a share of over 85%.

Biopharmaceuticals Contract Manufacturing Market Report Scope

 Report Coverage  Details
Market Size in 2024 USD 20.03 Billion
Market Size by 2033 USD 32.15 Billion
Growth Rate From 2024 to 2033 CAGR of 5.4%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Source, Service, Product, Therapeutic Area, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS Pharma; AGC Biologics; ProBioGen; Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Toyobo Co., Ltd.; Samsung BioLogics; Thermo Fisher Scientific, Inc.; Binex Co., Ltd.; WuXi Biologics; AbbVie, Inc; Novartis AG; ADMA Biologics, Inc.; Catalent, Inc; Cambrex Corporation; Pfizer Inc.; Siegfried Holding AG

 

The success of the biopharmaceutical market can be majorly attributed to the contract manufacturers. Reduction in the overall investment required to bring a new drug product to market, providing access to expensive technologies, quick entry of products into the markets, and greater flexibility are some advantages offered by contract manufacturing organizations (CMOs), which have prompted the companies to outsource their biopharmaceutical manufacturing.

Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd. 

Source Insights

The mammalian source segment led the market in 2023 and accounted for the highest share of 60.9%. Based on the source, the market is dived into mammalian and non-mammalian-based contract manufacturing. The intensive investigation that is being carried out on the usage of various sources and species for biopharmaceutical development is expected to drive market growth. The main objective of these investigations is to enhance the productivity and efficiency of biopharmaceutical manufacturing. Mammalian-based biomanufacturing contributed to a higher revenue share owing to the higher cost associated with obtaining products from these sources. Companies engaged in providing contract services using mammalian cell culture include AbbVie Contract Manufacturing, AMRI, Avid Bioservices, Boehringer Ingelheim Biopharmaceuticals Gmbh, and Catalent Pharma Solutions.

In addition to this, a major percentage of biopharmaceutical products that are in pipeline are mammalian expressed, hence expecting to maintain the dominance over the forecast period as well. Consequently, companies like Lonza and Charles River are making significant investments in the expansion of their mammalian cell culture manufacturing facilities for biologics and biosimilar development. For instance, in October 2017 Lonza acquired a clinical-stage mammalian manufacturing site in the United States from Shire plc. The plant is equipped with single-use bioreactors of 1,000L and 2,000L capacities, coupled with downstream purification capabilities.

Non-mammalian cell line -E. Coli is recognized as the widely adopted non-mammalian cell culture for biopharmaceutical production owing to its rapid access and cost-effective cultivation. The development of a transgenic non-mammalian expression system holds a great promise for the significant growth of this segment throughout the forecast period. Abbott Bioresearch, Avecia Biotechnology, BioReliance, Biovitrum AB, Dow Pharmaceutical, and Celltrion are a few companies working as CMOs using microbial cultures.

Service Insights

Process development services led the global market in 2023 and accounted for a share of about 34.7%. This is due to high capital expenditure in downstream processing. Moreover, downstream operations demand vigorous attention for final product recovery and purification steps to maintain product quality and prevent wastage. CMOs have provided biopharma players with a wide array of services ranging from cell cultivation to the final packaging of the product. The manufacturing services offered by CMOs are process development, fill & finish operations, analytical & QC studies, and packaging.

Process development services dominated in 2023 with respect to revenue with downstream processing leading the market. This is due to high capital expenditure in downstream processing. Moreover, downstream operations demand vigorous attention for final product recovery and purification steps, to maintain product quality and prevent wastage. With growing quality concerns and regulatory changes for biopharmaceutical development, analytical & QC studies are expected to grow lucratively during the forecast period. New regulations are being introduced for the production of biologics by CMOs in compliance with regulatory standards to maintain product purity and safety.

Product Insights

The biologics product segment led the market in 2023 with a share of over 85.0%. Contract manufacturers have played a vital role in the success of both biologics and biosimilars. This is majorly due to the huge commercial success of biologics, which is depicted through the presence of a large number of FDA-approved biologics in the market.

Among all the biologics, Monoclonal Antibodies (MAb) have captured the largest share in 2023. A high capital requirement for the construction of a MAb plant has accelerated the uptake of contract services for Mab production, thereby contributing to the major share of this segment.

However, biosimilars production is considered one of the key strategies for business expansion in comparison with biologics because investment in biosimilars manufacturing helps in the fast market reach of the biopharmaceuticals. Moreover, biosimilars have supported the biopharmaceutical CMO industry with respect to cost-saving advantages.

Regional Insights

With a high number of biomanufacturing facilities in the U.S., North America dominated with the largest revenue share of 37% in 2023. Furthermore, revenue from biopharmaceutical-based R&D activities held a major percentage of the total R&D carried out in various sectors in the U.S. Furthermore, interventions & conferences conducted in the region for pertinent technologies and issues in the application of biologics for the treatment of various chronic conditions are anticipated to positively influence regional growth.

However, Asian countries are expected to emerge as the attractive outsourcing location for the biomanufacturing of large molecules. Low manufacturing and operating cost offered by countries, like China & India, is one key factor driving the Asian market. Faster growth in the Korean market is expected to boost revenue generation from the APAC region.

Some of the prominent players in the Biopharmaceuticals Contract Manufacturing Market include:

  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • AGC Biologics
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Toyobo Co. Ltd.
  • Samsung BioLogics
  • Thermo Fisher Scientific, Inc.
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.
  • Novartis AG
  • ADMA Biologics, Inc.
  • Catalent, Inc
  • Cambrex Corporation
  • Pfizer Inc.
  • Siegfried Holding AG

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global Biopharmaceuticals Contract Manufacturing market.

By Source 

  • Mammalian
  • Non-mammalian

By Service 

  • Process Development
    • Downstream
    • Upstream
  • Fill & Finish Operations
  • Analytical & QC studies
  • Packaging

By Product 

  • Biologics
    • Monoclonal antibodies (MABs)
    • Recombinant Proteins
    • Vaccines
    • Antisense, RNAi, & Molecular Therapy
    • Others
  • Biosimilars

By Therapeutic Area 

  • Oncology
  • Autoimmune Diseases
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Neurology
  • Infectious Diseases
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1 Biopharmaceuticals Contract Manufacturing Market: Executive Summary

1.1 Market Snapshot

Chapter 2 Biopharmaceuticals Contract Manufacturing Market: Research Methodology

2.1 Information Procurement

2.1.1 Purchased Database

2.1.2 Internal Database

2.2 Data Analysis

2.3 Market Formulation & Validation

2.4 Approaches for Market Estimation

2.4.1 Approach 1: Commodity Flow & Bottom Up Approach

2.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 3 Biopharmaceuticals Contract Manufacturing Market: Variables, Trends& Scope

3.1 Market Segmentation &Scope

3.1.1 Market driver analysis

3.1.1.1 Rise in investment by CMOs for capacity expansion

3.1.1.2 Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals

3.1.1.2.1 Notable growth of biologics

3.1.1.3 Robust biopharmaceuticals pipeline

3.1.1.4 Cost and time saving benefits offered by contract services

3.1.2 Market restraint analysis

3.1.2.1 Limited outsourcing amongst well-established biopharmaceutical manufacturer

3.2 Opportunity analysis

3.2.1 Expansion of fill-and-finish CMOs

3.2.2 Emergence of single-use bioprocessing equipment & solutions

3.2.3 Funding & investments

3.3 Trend Analysis

3.3.1 Merger & acquisitions in CMO industry

3.3.2 Trading of CMOs at strong EV/EBITDA multiples

3.3.3 Current trends in biopharmaceutical industry

3.4 Pipeline Analysis

3.4.1 Distribution of products & projects in development stage by clinical phase

3.4.1.1 Key finding of the analysis:

3.4.2 Pipeline analysis for biosimilar drugs, as of February 2018

3.4.3 Total global biopharmaceutical R&D spending

3.4.4 Number of drugs in clinical development phase, 2015

3.5 Pricing Analysis for Process Development

3.5.1 Cell line/expression system pricing

3.5.2 Bioreactor cost

3.5.3 Operating and construction cost advantage due to single-use bioprocessing equipment

3.5.4 Bioprocessing operating cost items and ranges

3.5.5 Bioprocessing pricing analysis based on product type

3.5.6 Downstream bioprocessing pricing analysis

3.5.6.1 Cost analyses for buffer purchasing

3.6 Penetration &Growth Prospect Mapping for Contract Manufacturing Service, 2021

3.7 Biopharmaceuticals Contract Manufacturing Market -Swot Analysis, By Factor (Political & Legal, Economic And Technological)

3.8 Industry Analysis - Porter’s

3.9 Customer Relationship Management in Contract Manufacturing

3.9.1 Selection process of CMO

3.9.2 Operations and quality oversight of CMOs

Chapter 4 Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis

4.1 Global Biopharmaceuticals Contract Manufacturing Market: Source Movement Analysis

4.2 Mammalian Source

4.2.1 Global mammalian source market, 2021 - 2033

4.3 Non-mammalian Source

4.3.1 Global non-mammalian source market, 2021 - 2033

Chapter 5 Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis

5.1 Global Biopharmaceuticals Contract Manufacturing Market: Service Movement Analysis

5.2 Process development

5.2.1 Global process development market, 2021 - 2033

5.2.2 Downstream processing

5.2.2.1 Global downstream processing market, 2021 - 2033

5.2.3 Upstream processing

5.2.3.1 Global upstream processing market, 2021 - 2033

5.3 Fill & finish operations

5.3.1 Global fill & finish operations market, 2021 - 2033

5.4 Analytical & QC studies

5.4.1 Global analytical & QC studies market, 2021 - 2033

5.5 Packaging

5.5.1 Global contract packaging market, 2021 - 2033

Chapter 6 Biopharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis

6.1 Global Biopharmaceuticals Contract Manufacturing Market: Product Movement Analysis

6.2 Biologics

6.2.1 Global biologics market, 2021 - 2033

6.2.2 Monoclonal Antibodies

6.2.2.1 Global monoclonal antibodies market, 2021 - 2033

6.2.3 Recombinant proteins

6.2.3.1 Global recombinant proteins market, 2021 - 2033

6.2.4 Vaccines

6.2.4.1 Global vaccines market, 2021 - 2033

6.3 Antisense, RNAi, & molecular therapy

6.3.1 Global antisense, RNAi, & molecular therapy market, 2021 - 2033

6.3.2 Others

6.3.2.1 Global other product market, 2021 - 2033

6.4 Biosimilar

6.4.1 Global biosimilar market, 2021 - 2033

Chapter 7 Biopharmaceuticals Contract Manufacturing Market: Therapeutic area Estimates & Trend Analysis

7.1 Global Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Movement Analysis

7.2 Oncology

7.2.1 Global oncology market, 2021 - 2033

7.3 Autoimmune Diseases

7.3.1 Global autoimmune diseases market, 2021 - 2033

7.4 Metabolic Diseases

7.4.1 Global metabolic diseases market, 2021 - 2033

7.5 Cardiovascular Diseases

7.5.1 Global cardiovascular diseases market, 2021 - 2033

7.6 Neurology

7.6.1 Global neurology market, 2021 - 2033

7.7 Infectious Diseases

7.7.1 Global infectious diseases market, 2021 - 2033

7.8 Others

7.8.1 Global others market, 2021 - 2033

Chapter 8 Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis, by Service, Source, & Product

8.1 Biopharmaceuticals Contract Manufacturing Market Share by Region, 2021 & 2030

8.2 North America

8.2.1 North America biopharmaceuticals contract manufacturing market, 2021 - 2033

8.2.2 U.S.

8.2.2.1 U.S. biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.2.2.2 U.S. biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.2.2.3 U.S. biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.2.2.4 U.S. biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.2.3 Canada

8.2.3.1 Canada biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.2.3.2 Canada biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.2.3.3 Canada biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.2.3.4 Canada biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.3 Europe

8.3.1 Europe biopharmaceuticals contract manufacturing market, 2021 - 2033

8.3.2 Germany

8.3.2.1 Germany biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.3.2.2 Germany biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.3.2.3 Germany biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.3.2.4 Germany biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.3.3 France

8.3.3.1 France biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.3.3.2 France biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.3.3.3 France biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.3.3.4 France biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.3.4 UK

8.3.4.1 UK biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.3.4.2 UK biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.3.4.3 UK biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.3.4.4 UK biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.3.5 Italy

8.3.5.1 Italy biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.3.5.2 Italy biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.3.5.3 Italy biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.3.5.4 Italy biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.3.5 Spain

8.3.5.1 Spain biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.3.5.2 Spain biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.3.5.3 Spain biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.3.5.4 Spain biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.4 Asia Pacific

8.4.1 Asia Pacific biopharmaceuticals contract manufacturing market, 2021 - 2033

8.4.2 China

8.4.2.1 China biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.4.2.2 China biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.4.2.3 China biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.4.2.4 China biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.4.3 India

8.4.3.1 India biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.4.3.2 India biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.4.3.3 India biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.4.3.4 India biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.4.4 Japan

8.4.4.1 Japan biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.4.4.2 Japan biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.4.3.4 Japan biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.4.4.4 Japan biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.4.5 Australia

8.4.5.1 Australia biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.4.5.2 Australia biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.4.5.3 Australia biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.4.5.4 Australia biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033

8.4.6 South Korea

8.4.6.1 South Korea biopharmaceuticals contract manufacturing market, by source, 2021 - 2033 (USD Million)

8.4.6.2 South Korea biopharmaceuticals contract manufacturing market, by service, 2021 - 2033 (USD Million)

8.4.6.3 South Korea biopharmaceuticals contract manufacturing market, by product, 2021 - 2033 (USD Million)

8.4.6.4 South Korea biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

8.5 Latin America

8.5.1 Latin America biopharmaceuticals contract manufacturing market, 2021 - 2033

8.5.2 Brazil

8.5.2.1 Brazil biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.5.2.2 Brazil biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.5.2.3 Brazil biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.5.2.4 Brazil biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

8.5.3 Colombia

8.5.3.1 Colombia biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.5.3.2 Colombia biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.5.3.3 Colombia biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.5.3.4 Colombia biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

8.5.4 Argentina

8.5.4.1 Argentina biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.5.4.2 Argentina biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.5.4.3 Argentina biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.5.4.4 Argentina biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

8.5.5 Mexico

8.5.5.1 Mexico biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.5.5.2 Mexico biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.5.5.3 Mexico biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.5.5.4 Mexico biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

8.6 Middle East & Africa (MEA)

8.6.1 Middle East & Africa biopharmaceuticals contract manufacturing market, 2021 - 2033

8.6.2 South Africa

8.6.2.1 South Africa biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.6.2.2 South Africa biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.6.2.3 South Africa biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.6.2.4 South Africa biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

8.6.3 Saudi Arabia

8.6.3.1 Saudi Arabia biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.6.3.2 Saudi Arabia biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.6.3.3 Saudi Arabia biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.6.3.4 Saudi Arabia biopharmaceuticals contract manufacturing market, by therapeutic area, 3018 - 3060 (USD Million)

8.6.4 UAE

8.6.4.1 UAE biopharmaceuticals contract manufacturing market, by source, 2021 - 2033

8.6.4.2 UAE biopharmaceuticals contract manufacturing market, by service, 2021 - 2033

8.6.4.3 UAE biopharmaceuticals contract manufacturing market, by product, 2021 - 2033

8.6.4.4 UAE biopharmaceuticals contract manufacturing market, by therapeutic area, 2021 - 2033 (USD Million)

Chapter 9 Competitive Landscape

9.1 Strategy Framework

9.2 Market Participation Categorization

9.3 Company Profiles

9.3.1 Boehringer Ingelheim GmbH

9.3.1.1 Company overview

9.3.1.2 Financial performance

9.3.1.3 Product benchmarking

9.3.1.4 Strategic initiatives

9.3.2 Lonza

9.3.2.1 Company overview

9.3.2.2 Financial performance

9.3.2.3 Product benchmarking

9.3.2.4 Strategic initiatives

9.3.3 Inno Biologics Sdn Bhd

9.3.3.1 Company overview

9.3.3.2 Financial performance

9.3.3.3 Product benchmarking

9.3.3.4 Strategic initiatives

9.3.4 Rentschler Biotechnologie GmbH

9.3.4.1 Company overview

9.3.4.2 Financial performance

9.3.4.3 Product benchmarking

9.3.4.4 Strategic initiatives

9.3.5 JRS PHARMA

9.3.5.1 Company overview

9.3.5.1.1 CELONIC AG

9.3.5.2 Financial performance

9.3.5.2.1 Financial performance

9.3.5.3 Product benchmarking

9.3.5.4 Strategic initiatives

9.3.6 AGC Biologics

9.3.6.1 Company overview

9.3.6.2 BIOMEVA GmbH

9.3.6.2.1 Company overview

9.3.6.3 CMC Biologics

9.3.6.3.1 Company overview

9.3.6.4 Financial performance of AGC

9.3.6.4.1 Financial performance of BIOMEVA GmbH

9.3.6.4.2 Financial performance of CMC Biologics

9.3.6.5 Product benchmarking

9.3.6.6 Strategic initiatives

9.3.6.6.1 Biomeva GmbH

9.3.6.6.2 CMC Biologics

9.3.7 ProBioGen

9.3.7.1 Company overview

9.3.7.2 Financial performance

9.3.7.3 Product benchmarking

9.3.7.4 Strategic initiatives

9.3.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

9.3.8.1 Company overview

9.3.8.2 Financial performance

9.3.8.3 Product benchmarking

9.3.8.4 Strategic initiatives

9.3.9 TOYOBO CO., LTD.

9.3.9.1 Company overview

9.3.9.2 Financial performance

9.3.9.3 Product benchmarking

9.3.9.4 Strategic initiatives

9.3.10 Samsung BioLogics

9.3.10.1 Company overview

9.3.10.2 Financial performance

9.3.10.3 Product benchmarking

9.3.10.4 Strategic initiatives

9.3.11 Thermo Fisher Scientific, Inc.

9.3.11.1 Company Overview

9.3.11.2 Patheon

9.3.11.2.1 Company overview

9.3.11.1.1.1 DPx

9.3.11.3 Financial Performance of Thermo Fisher Scientific, Inc.

9.3.11.3.1 Financial performance of Patheon

9.3.11.4 Product benchmarking

9.3.11.5 Strategic initiatives

9.3.12 Binex Co., Ltd.

9.3.12.1 Company overview

9.3.12.2 Financial performance

9.3.12.3 Product benchmarking

9.3.13 WuXi Biologics

9.3.13.1 Company overview

9.3.13.2 Financial performance

9.3.13.3 Product benchmarking

9.3.13.4 Strategic initiatives

9.3.14 AbbVie, Inc.

9.3.14.1 Company overview

9.3.14.2 Financial performance

9.3.14.3 Product benchmarking

9.3.14.4 Strategic initiatives

9.3.15 Novartis AG

9.3.15.1 Company overview

9.3.15.2 Financial performance

9.3.15.3 Product benchmarking

9.3.15.4 Strategic initiatives

9.3.16 ADMA Biologics, Inc.

9.3.16.1 Company overview

9.3.16.2 Financial performance

9.3.16.3 Product benchmarking

9.3.16.4 Strategic initiatives

9.3.17 Catalent Inc.

9.3.17.1 Company overview

9.3.17.2 Financial performance

9.3.17.3 Product benchmarking

9.3.17.4 Strategic initiatives

9.3.18 Cambrex Corporation

9.3.18.1 Company overview

9.3.18.2 Financial performance

9.3.18.3 Product benchmarking

9.3.18.4 Strategic initiatives

9.3.19 Pfizer Inc.

9.3.19.1 Company overview

9.3.19.2 Financial performance

9.3.19.3 Product benchmarking

9.3.19.4 Strategic initiatives

9.3.20 Siegfried Holding AG

9.3.20.1 Company overview

9.3.20.2 Financial performance

9.3.20.3 Product benchmarking

9.3.20.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers